Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune diseases and cancers - Agrees terms on equity prepayment facility of up to GBP5 million with RiverFort Global Opportunities PCC Ltd, as arranged by RiverFort Global Capital Ltd, with an initial deposit of GBP2 million. This is expected on August 4, net of associated costs. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued Monday and not separately reported by Alliance News: Read More
Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune diseases and cancers - Announces successful dosing of first test subjects in a randomised, placebo-controlled phase 1a clinical trial for lead programme SDC-1801. SDC-1801 is a dual TYK2/JAK1 kinase inhibitor and potential new therapeutic for various autoimmune diseases with an initial focus on psoriasis. The phase 1a trial will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of SDC-1801 in healthy subjects, in single and multiple ascending oral dose studies. Dosing has started in a specialist clinical unit in Melbourne, Australia. Sareum expects full safety data to become available during the first half of 2024, after which a phase 1b clinical study will commence post-haste if the Phase 1a trial obtains satisfactory results. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
Alliance News) - Sareum Holdings PLC on Friday said its application to start a phase 1 clinical trial in Australia of its lead product, psoriasis drug SDC-1801, has been approved. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More
(Alliance News) - Sareum Holdings PLC on Wednesday reported an increased half-year loss for the six months to December 31, as it continued to work on its psorasis candidate drug SDC-1801. Read More
Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune disease and cancer - On Wednesday, says it has begun an application to perform phase one clinical studies on SDC-1801 in Australia under the clinical trial notification scheme. Read More
(Alliance News) - Sareum Holdings PLC on Monday said that GSK PLC subsidiary Sierra Oncology Inc has completed the return of the clinical study reports relating to SRA737 to Sarerum's co-development partner CRT Pioneer Fund LP. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More
Sareum Holdings PLC - Cambridge, England-based biotechnology company focused on developing kinase inhibitors for autoimmune disease & cancer - Says it is pleased by the publication of data from the Phase 1/2 trial of SRA737 as a combination treatment for advanced cancers in the medical journal, Clinical Cancer Research. Read More
Sareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - In the year ended June 30, pretax loss widens to GBP2.6 million from GBP1.7 million a year before. No revenue is recorded in either year, but in the previous year it brought in GBP171,000 in other operating income, with none recorded for financial 2022. Says it will discuss the future of SRA737 with partner Cancer Research Technology Pioneer Fund. Earlier this month, GSK PLC subsidiary Sierra Oncology Inc said it intends to return the rights for the SRA737 cancer treatment to CPF. Read More
(Alliance News) - Sareum Holdings PLC on Wednesday after Sierra Oncology Inc, a subsidiary of GSK PLC, said it intends to return the rights for SRA737 to the CRT Pioneer Fund LP. Read More
(Correcting that Bristol-Myers gained US FDA approval, not Sareum.) Read More
(Alliance News) - Sareum Holdings PLC on Monday said the US Food & Drug Administration has approved Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor. Read More
Sareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - Notes that GSK PLC has completed its acquisition of Sierra Oncology Inc, the licence holder of SRA737, for USD1.9 billion. SRA737 was discovered and initially developed by scientists at the Institute of Cancer Research in collaboration with Sareum. Read More
(Alliance News) - Midatech Pharma PLC on Friday said that Chair Rolf Stahel plans to leave the board on June 20, and it named Stephen Parker as his successor. Read More